Last reviewed · How we verify
Dexmedetomidine 0.5 microgram/kg
Dexmedetomidine 0.5 microgram/kg is a Alpha-2 adrenergic receptor agonist Small molecule drug developed by Sindh Institute of Urology and Transplantation. It is currently FDA-approved for Sedation of intubated and mechanically ventilated patients in intensive care units, Sedation and analgesia for procedural sedation, Perioperative anxiolysis and analgesia.
Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system.
Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system. Used for Sedation of intubated and mechanically ventilated patients in intensive care units, Sedation and analgesia for procedural sedation, Perioperative anxiolysis and analgesia.
At a glance
| Generic name | Dexmedetomidine 0.5 microgram/kg |
|---|---|
| Sponsor | Sindh Institute of Urology and Transplantation |
| Drug class | Alpha-2 adrenergic receptor agonist |
| Target | Alpha-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesia and Sedation |
| Phase | FDA-approved |
Mechanism of action
Dexmedetomidine binds with high selectivity to alpha-2 adrenergic receptors, particularly in the locus coeruleus and other brainstem regions, leading to decreased norepinephrine release and reduced neuronal firing. This results in a unique sedative state characterized by maintained airway reflexes and the ability to be aroused, along with analgesic and anxiolytic effects. The drug is commonly used for sedation in intensive care and procedural settings.
Approved indications
- Sedation of intubated and mechanically ventilated patients in intensive care units
- Sedation and analgesia for procedural sedation
- Perioperative anxiolysis and analgesia
Common side effects
- Hypotension
- Bradycardia
- Hypertension (transient, initial)
- Dry mouth
- Rebound hypertension on withdrawal
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexmedetomidine 0.5 microgram/kg CI brief — competitive landscape report
- Dexmedetomidine 0.5 microgram/kg updates RSS · CI watch RSS
- Sindh Institute of Urology and Transplantation portfolio CI
Frequently asked questions about Dexmedetomidine 0.5 microgram/kg
What is Dexmedetomidine 0.5 microgram/kg?
How does Dexmedetomidine 0.5 microgram/kg work?
What is Dexmedetomidine 0.5 microgram/kg used for?
Who makes Dexmedetomidine 0.5 microgram/kg?
What drug class is Dexmedetomidine 0.5 microgram/kg in?
What development phase is Dexmedetomidine 0.5 microgram/kg in?
What are the side effects of Dexmedetomidine 0.5 microgram/kg?
What does Dexmedetomidine 0.5 microgram/kg target?
Related
- Drug class: All Alpha-2 adrenergic receptor agonist drugs
- Target: All drugs targeting Alpha-2 adrenergic receptor
- Manufacturer: Sindh Institute of Urology and Transplantation — full pipeline
- Therapeutic area: All drugs in Anesthesia and Sedation
- Indication: Drugs for Sedation of intubated and mechanically ventilated patients in intensive care units
- Indication: Drugs for Sedation and analgesia for procedural sedation
- Indication: Drugs for Perioperative anxiolysis and analgesia
- Compare: Dexmedetomidine 0.5 microgram/kg vs similar drugs
- Pricing: Dexmedetomidine 0.5 microgram/kg cost, discount & access